Origin Biologics

What Origin Biologics does

Origin Biologics (also operating as Origin Bio) is a privately held biotechnology company headquartered in Las Vegas, Nevada, founded in 2016 with 11-50 employees. Firmographic descriptions reference a focus on musculoskeletal implants designed to restore biological and mechanical functionality; however, the company's most recent and substantiated strategic activity centers on AI-driven gene regulation rather than implant products, suggesting either a business pivot or a new product vertical.

The company's core product is Axis, a proprietary AI foundation model designed for gene regulation, launched on October 10, 2025. Axis is described as a multimodal AI model capable of processing and analyzing multiple types of biological and genetic data to interpret gene expression patterns. The product is positioned as a breakthrough with a novel method/architecture in AI-powered biotechnology. Axis is categorized as a generative AI capability, producing insights and predictions about genetic regulation patterns rather than purely analytical outputs.

No revenue model, pricing structure, customer segments, distribution channels, or management team information is publicly disclosed. The company has no disclosed funding rounds, partnerships, regulatory actions, or customer logos. Its commercial go-to-market motion, revenue mechanics, and customer base are entirely opaque in available sources. The firm appears to be at an early commercial or pre-commercial stage with a single recently-launched product.

Name

Origin Biologics

Website

https://originbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Origin Biologics is a private Las Vegas-based biotechnology company that has developed Axis, a proprietary AI foundation model for gene regulation analysis, targeting biotech researchers and life sciences organizations. The company operates with 11-50 employees and launched its single core AI product in October 2025.

Ownership category

akta.pro rank

Product category

Computational Biology AI Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• AI gene regulation
• Biotechnology research
• Genetic data analysis
• AI foundation models
• Computational biology

Headquarters

HQ city

Las Vegas

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Core offering

Origin Biologics develops and offers Axis, an AI foundation model designed for gene regulation. Axis processes and analyzes genetic and biological data to generate insights and predictions related to gene expression patterns and biological processes, targeting biotech researchers and companies.

Product overview

Origin Biologics offers Axis, an AI-powered platform for gene regulation analysis. The company operates as a single-product biotechnology firm focused on applying artificial intelligence to biological research and genetic analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• Axis Axis is a multimodal AI foundation model that processes genetic and biological data to analyze and interpret gene regulation and gene expression patterns. It is targeted at researchers and biotech companies working on biological research and genetic analysis.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Recent moves2 records

Expansion highlights3 records

Emerging players

• Owkin: Applies AI to biological and clinical data for drug discovery and translational research. Comparable as an emerging AI-bio company targeting pharma R&D use cases.

Direct peers

• Insitro: Machine learning-driven drug discovery combining computational models with biological data. Comparable as an ML-for-biology platform targeting pharma R&D.
• Profluent: Applies deep learning to protein and gene design, with foundation-model approaches to biological sequence generation. Directly comparable to Origin Biologics as an AI-first biology platform.
• Cradle: AI platform focused on protein engineering and biological sequence design for biotech customers. Overlaps with Axis on AI-enabled biological sequence/regulation modeling.
• EvolutionaryScale: Builds frontier AI foundation models for biology, including protein and potentially regulatory sequence design. Direct competitor in AI-driven biological foundation models and the most head-to-head comparable to Axis.
• Generate:Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple modalities. Closely comparable AI-for-biologics company pursuing foundation-model style approaches.

Broad incumbents

• Exscientia: AI-driven small-molecule drug discovery company with established pharma partnerships. Comparable as a publicly known AI-drug-discovery peer, though focused on chemistry rather than gene regulation.
• Recursion Pharmaceuticals: Large-cap AI-driven drug discovery company combining high-throughput biology with ML. Comparable as a broad AI-bio platform pursuing pharma partnerships.
• DeepMind (Alphabet): Developer of AlphaFold and AlphaGenome — dominant foundation models for protein structure and gene regulation. Represents the principal large-scale competitive threat to any AI-gene-regulation platform.
• AbCellera: AI/ML-enabled antibody discovery platform with deep pharma partnerships. Comparable business model — ML-driven biological discovery sold to pharma customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Origin Biologics